[CAS NO. 17902-23-7] Tegafur

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [17902-23-7]

Catalog

HY-17400

Brand

MCE

CAS

17902-23-7

DESCRIPTION [17902-23-7]

Overview

MDL	MFCD00012351
Molecular Weight	200.17
Molecular Formula	C8H9FN2O3
SMILES	O=C1NC(C(F)=CN1C2OCCC2)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]J Mol Med (Berl). 2019 Aug;97(8):1183-1193.

Summary

Tegafur (FT 207; NSC 148958) is a chemotherapeutic 5-FU prodrug used in the treatment of cancers; is a component of tegafur-uracil.

IC50 & Target

Nucleoside antimetabolite/analog

In Vitro

Tegafur is bioactivated to 5-FU by liver microsomal cytochrome P450 enzymes. 5-FU is subsequently converted into its active metabolites 5-fluoro-deoxyuridine-monophosphate (FdUMP) and 5-fluorouridine-triphosphate (FUTP) intracellularly; these metabolites inhibit the enzyme thymidylate synthase and intercalate into RNA, resulting in decreased thymidine synthesis, reduced DNA synthesis, disrupted RNA function, and tumor cell cytotoxicity.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03175679	Beijing YouAn Hospital	Hepatocellular Carcinoma	May 1, 2017	Phase 1
NCT02749526	The First Affiliated Hospital with Nanjing Medical University	Esophageal	April 2016	Phase 2
NCT03175705	Beijing YouAn Hospital	Hepatocellular Carcinoma	May 1, 2017	Phase 1
NCT00905047	Centre Oscar Lambret	Colorectal Cancer	September 2005	Phase 3
NCT05325528	Zhejiang University	Liver Metastases	April 21, 2022	Phase 2\|Phase 3
NCT03406299	National Health Research Institutes, Taiwan	Biliary Tract Neoplasms	April 19, 2018	Phase 2
NCT03204019	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Pancreatic Neuroendocrine Tumor	October 2016	Phase 2
NCT00378716	NSABP Foundation Inc\|National Cancer Institute (NCI)	Colorectal Cancer	February 1997	Phase 3
NCT00207831	Institut Cancerologie de l´Ouest\|Merck Sharp & Dohme LLC	Rectal Cancer\|Stage II+III\|T3 or T4 (Only Anal Extension) Rectal Cancer\|N0-2\|M0	July 2004	Phase 3
NCT03267121	Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University	Head and Neck Squamous Cell Carcinoma	October 1, 2017	Phase 2
NCT05070598	Shengjing Hospital	HER2-positive Gastric Cancer	September 7, 2021	Phase 2
NCT04216758	Fudan University	Stage IA Pancreatic Adenocarcinoma\|Stage IB Pancreatic Adenocarcinoma\|Stage IIA Pancreatic Adenocarcinoma\|Stage IIB Pancreatic Adenocarcinoma	January 1, 2020	Phase 2
NCT01492543	Cancer Institute and Hospital, Chinese Academy of Medical Sciences\|Peking University Cancer Hospital & Institute\|Beijing Chao Yang Hospital\|Chinese PLA General Hospital\|China-Japan Friendship Hospital\|Tianjin Medical University Cancer Institute and Hospital\|Hebei Tumor Hospital	Breast Cancer	December 2011	Phase 2
NCT03702491	Eastern Hepatobiliary Surgery Hospital	Gallbladder Carcinoma	August 10, 2018	Phase 2
NCT05223088	Fujian Cancer Hospital	Immunotherapy\|Gastrict Cancer	October 31, 2021	Phase 2
NCT04515615	Yu jiren\|First Affiliated Hospital of Zhejiang University	Gastric Cancer Stage III	September 9, 2020	Phase 2
NCT04135781	Zhejiang Cancer Hospital\|CSPC Ouyi Pharmaceutical Co., Ltd.	Stomach Cancer	March 1, 2020	Phase 3
NCT03096184	Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University	Head and Neck Squamous Cell Carcinoma	December 23, 2016	Phase 2
NCT05451290	First Affiliated Hospital of Zhejiang University	Advanced Biliary Tract Carcinoma	September 1, 2022	Phase 2
NCT03204032	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Extrapancreatic Neuroendocrine Tumor	October 2016	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : ≥ 48 mg/mL ( 239.80 mM )

H ₂ O : ≥ 20 mg/mL ( 99.92 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.9958 mL	24.9788 mL	49.9575 mL
5 mM	0.9992 mL	4.9958 mL	9.9915 mL
10 mM	0.4996 mL	2.4979 mL	4.9958 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (12.49 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (12.49 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (12.49 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-

Uracil, 5-fluoro-1-(tetrahydro-2-furyl)-

5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione

N¹-(2-Tetrahydrofuryl)-5-fluorouracil

Fluorofur

FT 207

5-Fluoro-1-(tetrahydro-2-furyl)uracil

N¹-(2′-Tetrahydrofuryl)-5-fluorouracil

Futraful

NSC 148958

5-Fluoro-1-(2-tetrahydrofuranyl)uracil

1-(Tetrahydro-2-furanyl)-5-fluorouracil

Tegafur

5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione

1-(Tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione

Fluaid

Ftorafur

Fluorafur

1-(2-Tetrahydrofuryl)-5-fluorouracil

N¹-(2-Tetrahydrofuranyl)-5-fluorouracil

5-Fluoro-1-(tetrahydro-2′-furyl)uracil

Racemic Ftorafur

Furofutran

Riol

Fulaid

Citofur

Lamar

Coparogin

Fulfeel

Neberk

Furafluor

Fental

Sinoflurol

MJF 12264

Nitobanil

Exonal

Franrose

Lifril

Tefsiel C

Sunfural

TS 1

Utefos